A Phase I/II clinical trial also found that ADH‐1 treatment, in combination with isolated limb intravenous infusion of melphalan improved initial response rates in patients with advanced melanoma, when compared with melphalan alone.23, 24. Here, ADH1A is linked to melanoma.